Compare Incyte Corporation (INCY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tesla, Inc. — how do they compare? Incyte Corporation trades at $120.93 (market cap $24.54B), while Tesla, Inc. trades at $326.36 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 53.4× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | TSLA | |
|---|---|---|
Market Cap | $24.54B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $489.88 |
52-Week Low | $81.61 | $298.16 |
Enterprise Value | $20.04B | $1.29T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Tesla (TSLA) trades at $326.58, down 1.3% over the past 24 hours, with a bearish technical signal driven by moving averages. The stock shows elevated valuation ratios, including a P/E of 308.16 and P/S of 11.36, while recent earnings performance was mixed with a Q2 2026 miss. Cash flow trends indicate heavy capital expenditure, and revenue growth has slowed, with net income margin at 3.67% for 2025. Recent news highlights regulatory approval for driver-assistance software in Europe and discussions on Tesla's strategic pivot toward AI and robotics.
Tesla faces near-term headwinds from valuation concerns and competitive pressures, but long-term growth potential hinges on autonomous driving technology and energy segment expansion. Key risks include execution challenges in new business lines and macroeconomic sensitivity. Analyst consensus is mixed with a $393.87 price target, suggesting cautious optimism amid high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
